SCHEMBL653653

SCHEMBL653653

COc1ccc(S(=O)(=O)n2ccc3ccnc(-c4ccc(C=O)o4)c32)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 1/20 0.68
TUBB P07437 1/20 0.68
TUBA3C P0DPH7 1/20 0.68
TUBA1B P68363 1/20 0.68
TUBA4A P68366 1/20 0.68
TUBB4B P68371 1/20 0.68
TUBB3 Q13509 1/20 0.68
TUBB2A Q13885 1/20 0.68
TUBB8 Q3ZCM7 1/20 0.68
TUBA3E Q6PEY2 1/20 0.68
TUBA1A Q71U36 1/20 0.68
TUBA1C Q9BQE3 1/20 0.68
TUBB6 Q9BUF5 1/20 0.68
TUBB2B Q9BVA1 1/20 0.68
TUBB1 Q9H4B7 1/20 0.68
HTR6 P50406 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
POLB P06746 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL652355 0.81 TUBB4A (0.73) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL650441 0.81 TUBB4A (1.00) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL10019348 0.79 TUBB4A (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL653473 0.79 TUBB4A (0.69) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL650056 0.79 TUBB4A (0.72) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL653340 0.77 TUBB4A (0.67) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL653946 0.77 TUBB4A (0.67) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL651693 0.77 TUBB4A (0.67) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL12904686 0.77 TUBB4A (0.66) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL650403 0.76 TUBB4A (0.65) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604145-B2 High activity, low molecular weight olefin polymerization process DOW GLOBAL TECHNOLOGIES, LLC (US) 2013-12-10 US disclosed
EP-1931686-B1 HIGH ACTIVITY, LOW MOLECULAR WEIGHT OLEFIN POLYMERIZATION PROCESS DOW GLOBAL TECHNOLOGIES LLC (US) 2012-08-01 EP disclosed
US-20120116035-A1 HIGH ACTIVITY, LOW MOLECULAR WEIGHT OLEFIN POLYMERIZATION PROCESS DOW GLOBAL TECHNOLOGIES LLC (US) 2012-05-10 US disclosed
US-8119748-B2 metal complexes such as Hafnium, [N-[2,6-bis(1-methylethyl)phenyl]- alpha -[2,4,6-trimethylphenyl]-6-(phenyl- kappa -C2)-2-pyridinemethaneaminato(2-),N1, kappa N2]dichloride, used as polymerization catalysts, for the production of isotactic addition copolymers, having toughness DOW GLOBAL TECHNOLOGIES LLC (US) 2012-02-21 US disclosed
US-8119683-B2 Aryl substituted sulfonamide compounds and their use as anticancer agents TAIPEI MEDICAL UNIVERSITY (TW) 2012-02-21 US disclosed
US-8119683-B2 Aryl substituted sulfonamide compounds and their use as anticancer agents TAIPEI MEDICAL UNIVERSITY (TW) 2012-02-21 US disclosed
US-20110039880-A1 ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TAIPEI MEDICAL UNIVERSITY (TW) 2011-02-17 US disclosed
US-20110039880-A1 ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TAIPEI MEDICAL UNIVERSITY (TW) 2011-02-17 US disclosed
WO-2011019634-A2 ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TAIPEI MEDICAL UNIVERSITY (TW) 2011-02-17 WO disclosed
WO-2011019634-A2 ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TAIPEI MEDICAL UNIVERSITY (TW) 2011-02-17 WO disclosed
US-20080255329-A1 High Activity, Low Molecular Weight Olefin Polymerization Process DOW GLOBAL TECHNOLOGIES LLC 2008-10-16 US disclosed
EP-1931686-A2 HIGH ACTIVITY, LOW MOLECULAR WEIGHT OLEFIN POLYMERIZATION PROCESS Dow Global Technologies Inc. (US) 2008-06-18 EP disclosed
WO-2007037944-A2 HIGH ACTIVITY, LOW MOLECULAR WEIGHT OLEFIN POLYMERIZATION PROCESS DOW GLOBAL TECHNOLOGIES INC. (US) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039880-A1 ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS ARSA, SULT1E1, STS TUBB4A 724/4885TUBB 1043/4885TUBA3C 1079/4885
US-20080255329-A1 High Activity, Low Molecular Weight Olefin Polymerization Process ACP1, ALOX12, ALOX15B TUBB4A 1078/4885TUBB 2140/4885TUBA3C 2108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.